In this article, we are going to take a look at where Apellis Pharmaceuticals (NASDAQ:APLS) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” ...

The shares were sold at an average price of $29.96, for a total value of $51,830.80. Following the sale, the chief financial officer now owns 86,370 shares in the company, valued at $2,587,645.20.

Apellis Pharmaceuticals stock opened at $26.00 on Thursday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The company has a market ...

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other oversold pharma stocks to buy according to analysts. On February 20 ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last reporting period, rising from 17.06M to 17.34M. This put 19.09% of the company's publicly available shares short.

APELLIS PHARMACEUTICALS ($APLS) is expected to release its quarterly earnings data on Friday, February 28th before market open, per Finnhub. Analysts are expecting ...